U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch) · United States

FDA Rx Promotion - Comparative and Uniqueness Claims

Claims that a prescription product is safer, more effective, the only or the first compared with other products require substantial evidence, normally head-to-head data, and must be accurately qualified; compounded drugs must not be marketed as FDA-approved or equivalent to a brand.

21 U.S.C. 352(a), (n), (bb); 21 CFR 202.1(e)(5), (e)(6)(ii)

What is FDA Rx Promotion - Comparative and Uniqueness Claims?

Claims that a prescription product is safer, more effective, the only or the first compared with other products require substantial evidence, normally head-to-head data, and must be accurately qualified; compounded drugs must not be marketed as FDA-approved or equivalent to a brand. Apply to prescription drug and compounded drug ads, web pages, emails and social posts that compare products or

US Federal

Read official source

Last reviewed: 2026-11-05

General information, not legal advice.

Who does this rule apply to?

general_audience, general_adults_18plus, customers, health_professionals, patients · Prescription Drug · pharma

Where does this rule apply?

United States

Which marketing channels are covered?

all_channels

When does this rule take effect?

2026-10-07

What does this rule require?

Claims that a prescription product is safer, more effective, the only or the first compared with other products require substantial evidence, normally head-to-head data, and must be accurately qualified; compounded drugs must not be marketed as FDA-approved or equivalent to a brand.

How can marketing teams comply?

Apply to prescription drug and compounded drug ads, web pages, emails and social posts that compare products or make first, only or best claims.

Where can I read the official source?

Read official source

Key facts

Regulatory authority
U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch)
Jurisdiction
United States
Official citation
21 U.S.C. 352(a), (n), (bb); 21 CFR 202.1(e)(5), (e)(6)(ii)
Published
2026-11-16
Effective date
2026-10-07
Channel
all_channels
Products
Prescription Drug
Audiences
general_audience, general_adults_18plus, customers, health_professionals, patients

Frequently asked questions

What is FDA Rx Promotion - Comparative and Uniqueness Claims?

Claims that a prescription product is safer, more effective, the only or the first compared with other products require substantial evidence, normally head-to-head data, and must be accurately qualified; compounded drugs must not be marketed as FDA-approved or equivalent to a brand.

Who does this rule apply to?

general_audience, general_adults_18plus, customers, health_professionals, patients · Prescription Drug · pharma

Where does this rule apply?

United States

Which marketing channels are covered?

all_channels

When does this rule take effect?

2026-10-07

Request a free compliance scan of your homepage and book a time with Warrant.

Get a free homepage compliance scan